RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias

FDA IND clearance enables RiboX to start a Phase 1 trial of RXIM002, a targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. The update positions RXIM002 as the first circular RNA-based in vivo CAR-T program to receive FDA IND clearance. Overall, the clearance is a clear de-risking milestone that should support investor confidence in the program’s early clinical pathway.

Analysis

FDA IND clearance enables RiboX to start a Phase 1 trial of RXIM002, a targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. The update positions RXIM002 as the first circular RNA-based in vivo CAR-T program to receive FDA IND clearance. Overall, the clearance is a clear de-risking milestone that should support investor confidence in the program’s early clinical pathway.